Skyrizi

RSS

risankizumab

Authorised
This medicine is authorised for use in the European Union.

Overview

Skyrizi is a medicine used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. It is used in adults with moderate to severe disease and who require systemic treatment (treatment with medicines given by mouth or by injection).

Skyrizi contains the active substance risankizumab.

This EPAR was last updated on 26/06/2019

Authorisation details

Product details
Name
Skyrizi
Agency product number
EMEA/H/C/004759
Active substance
Risankizumab
International non-proprietary name (INN) or common name
risankizumab
Therapeutic area (MeSH)
Psoriasis
Anatomical therapeutic chemical (ATC) code
L04AC
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
AbbVie Deutschland GmbH & Co. KG
Date of issue of marketing authorisation valid throughout the European Union
26/04/2019
Contact address

Knollstrasse 50
67061 Ludwigshafen am Rhein
Germany

Product information

26/04/2019 Skyrizi - EMEA/H/C/004759 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Assessment history

How useful was this page?

Add your rating
Average
1 rating